Review




Structured Review

Myriad Genetics endopredict (ep)/epclin
Predictive gene tests used in breast cancer care.
Endopredict (Ep)/Epclin, supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict+(ep)/endopredict/pmc10608445-37-0-3
Average 90 stars, based on 1 article reviews
endopredict (ep)/epclin - by Bioz Stars, 2026-11
90/100 stars

Images

1) Product Images from "The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer"

Article Title: The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer

Journal: Journal of Personalized Medicine

doi: 10.3390/jpm13101476

Predictive gene tests used in breast cancer care.
Figure Legend Snippet: Predictive gene tests used in breast cancer care.

Techniques Used: Adjuvant, Microarray, Immunohistochemistry

Related Articles

Introduce:

Article Title: Assessing the Performance of the PREDICT Breast Version 3.0 Prognostic Tool in Patients With Breast Cancer in the United States.
Article Snippet: Background: PREDICT Breast version 3 (v3) is the latest updated prognostication tool, developed using data from approximately 35,000 women diagnosed with breast cancer between 2000 and 2018 in the United Kingdom.. Although an earlier version of PREDICT was tested in the United States, the performance of the latest version remains unknown.. This study aims to validate PREDICT Breast v3 using newly released SEER outcome data for patients with breast cancer in the United States and to address potential health disparities.Methods:A total of 615,865 female patients diagnosed with primary breast cancer between 2000 and 2018 and followed for at least 10 years were selected from the SEER database.

Gene Expression:

Article Title: Assessing the Performance of the PREDICT Breast Version 3.0 Prognostic Tool in Patients With Breast Cancer in the United States.
Article Snippet: Background: PREDICT Breast version 3 (v3) is the latest updated prognostication tool, developed using data from approximately 35,000 women diagnosed with breast cancer between 2000 and 2018 in the United Kingdom.. Although an earlier version of PREDICT was tested in the United States, the performance of the latest version remains unknown.. This study aims to validate PREDICT Breast v3 using newly released SEER outcome data for patients with breast cancer in the United States and to address potential health disparities.Methods:A total of 615,865 female patients diagnosed with primary breast cancer between 2000 and 2018 and followed for at least 10 years were selected from the SEER database.

PAM50 Assay:

Article Title: Advances in Breast Cancer Diagnostics: From Screening to Precision Medicine.
Article Snippet: .. Prosigna (NanoString Technologies, Bothell, DC, USA), the PAM50-based assay generating a Risk https://doi.org/10.3390/diagnostics16081181 of Recurrence (ROR) score and intrinsic subtype classification, and EndoPredict (Myriad Genetics, Salt Lake City, UT, USA), an 11-gene assay incorporating tumor size and nodal status into the EPclin score, complete the commercially validated landscape [79,80]. .. MammaPrint (Agendia, Amsterdam, The Netherlands) is a 70-gene microarray assay classifying tumors as Low-Risk or High-Risk.

Article Title: Advances in Breast Cancer Diagnostics: From Screening to Precision Medicine
Article Snippet: .. Prosigna (NanoString Technologies, Bothell, DC, USA), the PAM50-based assay generating a Risk of Recurrence (ROR) score and intrinsic subtype classification, and EndoPredict (Myriad Genetics, Salt Lake City, UT, USA), an 11-gene assay incorporating tumor size and nodal status into the EPclin score, complete the commercially validated landscape [ , ]. ..



Similar Products

90
Myriad Genetics endopredict ep
Endopredict Ep, supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict+(ep)/endopredict+ep/pm40644891-340-0-2
Average 90 stars, based on 1 article reviews
endopredict ep - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Myriad Genetics endopredict® (ep)
Endopredict® (Ep), supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict+(ep)/endopredict+ep/pm38587783-23-0-2
Average 90 stars, based on 1 article reviews
endopredict® (ep) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Myriad Genetics endopredict (ep)/epclin
Predictive gene tests used in breast cancer care.
Endopredict (Ep)/Epclin, supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict+(ep)/endopredict/pmc10608445-37-0-3
Average 90 stars, based on 1 article reviews
endopredict (ep)/epclin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sividon Diagnostics GmbH 12-gene assay endopredict® ep
Predictive gene tests used in breast cancer care.
12 Gene Assay Endopredict® Ep, supplied by Sividon Diagnostics GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict+(ep)/12+gene+risk+score+endopredict/pm36976899-76-0-5
Average 90 stars, based on 1 article reviews
12-gene assay endopredict® ep - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sividon Diagnostics GmbH endopredict® (12-ep)
Predictive gene tests used in breast cancer care.
Endopredict® (12 Ep), supplied by Sividon Diagnostics GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict+(ep)/endopredict+++12+ep+/pmc09486269-4-0-12
Average 90 stars, based on 1 article reviews
endopredict® (12-ep) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Myriad Genetics endopredict (ep)
Commercially available multiparameter gene expression assays.
Endopredict (Ep), supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict+(ep)/endopredict+ep/pmc08366126-57-45-47
Average 90 stars, based on 1 article reviews
endopredict (ep) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Predictive gene tests used in breast cancer care.

Journal: Journal of Personalized Medicine

Article Title: The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer

doi: 10.3390/jpm13101476

Figure Lengend Snippet: Predictive gene tests used in breast cancer care.

Article Snippet: EndoPredict (EP)/EPclin , Myriad Genetics , 12 , RT-qPCR , RNA from FFPE tumour tissue , Postmenopausal women with early HR+/HER2 breast cancer who have been on ET for 5 years , Yes (1–3 positive nodes) , EP score , EP score of 0 to <5 low risk, EP 5 to 15 high risk; EPclin < 3.3 low risk, EPclin ≥ 3.3 high risk , Benefit from adjuvant chemotherapy , Risk of distant and late recurrence after 10 and 15 years.

Techniques: Adjuvant, Microarray, Immunohistochemistry

Commercially available multiparameter gene expression assays.

Journal: Therapeutic Advances in Medical Oncology

Article Title: The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

doi: 10.1177/17588359211038467

Figure Lengend Snippet: Commercially available multiparameter gene expression assays.

Article Snippet: This review will summarize the clinical utility of several commonly used multiparameter gene expression assays , including the Oncotype DX Recurrence Score (RS) (Genomic Health, Exact Sciences, Madison WI), MammaPrint (Agendia, Inc., Irvine, CA), PAM50 Risk of Recurrence (ROR) score (Prosigna, Veracyte, San Francisco, CA), EndoPredict (EP) (Myriad Genetics, Salt Lake City, UT), and Breast Cancer Index (BCI) (Biotheranostics, Inc., San Diego, CA), in early hormone receptor-positive (HR+) HER2 negative BCA.

Techniques: Gene Expression

Selected clinical trials evaluating gene expression assays.

Journal: Therapeutic Advances in Medical Oncology

Article Title: The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

doi: 10.1177/17588359211038467

Figure Lengend Snippet: Selected clinical trials evaluating gene expression assays.

Article Snippet: This review will summarize the clinical utility of several commonly used multiparameter gene expression assays , including the Oncotype DX Recurrence Score (RS) (Genomic Health, Exact Sciences, Madison WI), MammaPrint (Agendia, Inc., Irvine, CA), PAM50 Risk of Recurrence (ROR) score (Prosigna, Veracyte, San Francisco, CA), EndoPredict (EP) (Myriad Genetics, Salt Lake City, UT), and Breast Cancer Index (BCI) (Biotheranostics, Inc., San Diego, CA), in early hormone receptor-positive (HR+) HER2 negative BCA.

Techniques: Clinical Proteomics, Gene Expression, Adjuvant, Comparison

Clinical practice guidelines for use of gene expression assays to guide adjuvant chemotherapy recommendations.

Journal: Therapeutic Advances in Medical Oncology

Article Title: The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

doi: 10.1177/17588359211038467

Figure Lengend Snippet: Clinical practice guidelines for use of gene expression assays to guide adjuvant chemotherapy recommendations.

Article Snippet: This review will summarize the clinical utility of several commonly used multiparameter gene expression assays , including the Oncotype DX Recurrence Score (RS) (Genomic Health, Exact Sciences, Madison WI), MammaPrint (Agendia, Inc., Irvine, CA), PAM50 Risk of Recurrence (ROR) score (Prosigna, Veracyte, San Francisco, CA), EndoPredict (EP) (Myriad Genetics, Salt Lake City, UT), and Breast Cancer Index (BCI) (Biotheranostics, Inc., San Diego, CA), in early hormone receptor-positive (HR+) HER2 negative BCA.

Techniques: Gene Expression, Adjuvant